Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | CCR1 | P32246 | 1/20 | 0.43 |
| ▸ | CCR8 | P51685 | 1/20 | 0.43 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | GRM5 | P41594 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22482055 | 0.84 | PGK1 (0.43) | NOS2NPSR1 | |
| SCHEMBL2010535 | 0.81 | CCR1 (0.44) | SMN1; SMN2CCR1CCR8NOS3NOS2 | |
| SCHEMBL943326 | 0.80 | — | — | |
| SCHEMBL6193822 | 0.80 | SMN1; SMN2 (0.45) | SMN1; SMN2CCR1CCR8NOS3NOS2 | |
| SCHEMBL17429701 | 0.79 | CCR1 (0.43) | SMN1; SMN2CCR1CCR8NOS3NOS2 | |
| SCHEMBL13879249 | 0.78 | NOS2 (0.43) | SMN1; SMN2CCR1CCR8NOS3NOS2 | |
| SCHEMBL6195640 | 0.77 | KCNH2 (0.43) | SMN1; SMN2CCR1CCR8NOS3NOS2 | |
| SCHEMBL24259223 | 0.76 | KCNH2 (0.46) | SMN1; SMN2CCR1CCR8NOS3NOS2 | |
| SCHEMBL243243 | 0.76 | — | — | |
| SCHEMBL20730061 | 0.75 | PGK1 (0.41) | CCR1NPSR1MPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4514802-A1 | IMIDAZOLE DERIVATIVES AS ALK5 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2025-03-05 | — | — | EP | disclosed |
| WO-2023247592-A1 | 5-(4-FLUOROPHENYL)-2,3-DIHYDRO-1H-IMIDAZO[1,2-A]IMIDAZOLE DERIVATIVES AS ALK INHIBITORS FOR THE TREATMENT OF FIBROSIS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023208986-A1 | IMIDAZOLE DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-11-02 | — | — | WO | disclosed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-11471867-B2 | Ligand for forming ruthenium complex, ruthenium complex catalyst, production method therefor and use thereof | GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2022-10-18 | — | — | US | disclosed |
| WO-2022076905-A1 | ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| EP-3820474-A1 | ADENOSINE RECEPTOR BINDING COMPOUNDS | Nikang Therapeutics, Inc. (US) | 2021-05-19 | — | — | EP | disclosed |
| EP-3774782-A2 | ATF6 INHIBITORS AND USES THEREOF | Black Belt TX Ltd (GB) | 2021-02-17 | — | — | EP | disclosed |
| US-20200360911-A1 | LIGAND FOR FORMING RUTHENIUM COMPLEX, RUTHENIUM COMPLEX CATALYST, PRODUCTION METHOD THEREFOR AND USE THEREOF | GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2020-11-19 | — | — | US | disclosed |
| EP-3057948-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | Eisai R&D Management Co., Ltd. (JP) | 2016-08-24 | — | — | EP | disclosed |
| WO-2008074418-A2 | BISOXIMES AS FUNGICIDES AND ARTHROPODICIDES | BAYER CROPSCIENCE AKTENGESELLSCHAFT (DE) | 2008-06-26 | — | — | WO | disclosed |
| US-7087626-B2 | Pyrrole derivatives as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2006-08-08 | — | — | US | disclosed |
| EP-1601676-A2 | FUSED IMIDAZOLES AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | Pfizer Products Inc. (US) | 2005-12-07 | — | — | EP | disclosed |
| EP-1542994-A1 | NOVEL TRIAZOLE AND OXAZOLE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITOR | Pfizer Products Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| EP-1542684-A2 | NOVEL PYRAZOLE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | Pfizer Products Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| WO-2004078110-A2 | FUSED IMIZADOLES AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | PFIZER PRODUCTS INC. (US) | 2004-09-16 | — | — | WO | disclosed |
| WO-2004026863-A1 | NOVEL OXAZOLE AND THIAZOLE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | PFIZER PRODUCTS INC. (US) | 2004-04-01 | — | — | WO | disclosed |
| WO-2004026306-A2 | PYRAZOLE DERIVATIVES AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | PFIZER PRODUCTS INC. (US) | 2004-04-01 | — | — | WO | disclosed |
| EP-0974602-B1 | Catalyst and process for hydrogenating olefinically unsaturated compound | JSR CORP (JP) | 2004-01-02 | — | — | EP | disclosed |
| CN-1281436-A | N-Benzyl-3-indenylacetamides derivatives for treating neoplasia | CELL PATHWAYS INC (US) | 2001-01-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133132-A1 | NAMPT MODULATORS | NAMPT, MC4R, SIRT1 | SMN1; SMN2 1161/4885CCR1 4148/4885CCR8 4238/4885 |
| US-11471867-B2 | Ligand for forming ruthenium complex, ruthenium complex catalyst, production method therefor and use thereof | NOTUM, WEE2, WEE1 | SMN1; SMN2 4861/4885CCR1 2048/4885CCR8 1824/4885 |
| US-20200360911-A1 | LIGAND FOR FORMING RUTHENIUM COMPLEX, RUTHENIUM COMPLEX CATALYST, PRODUCTION METHOD THEREFOR AND USE THEREOF | NOTUM, WEE2, WEE1 | SMN1; SMN2 4861/4885CCR1 2048/4885CCR8 1824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.